Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to redu… Read more
Oragenics Inc (OGEN) - Net Assets
Latest net assets as of September 2025: $9.83 Million USD
Based on the latest financial reports, Oragenics Inc (OGEN) has net assets worth $9.83 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.71 Million) and total liabilities ($2.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.83 Million |
| % of Total Assets | 77.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.26% |
| 10-Year Change | -104.48% |
| Growth Volatility | 89.65 |
Oragenics Inc - Net Assets Trend (2003–2024)
This chart illustrates how Oragenics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oragenics Inc (2003–2024)
The table below shows the annual net assets of Oragenics Inc from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-211.88K | -106.69% |
| 2023-12-31 | $3.17 Million | -75.65% |
| 2022-12-31 | $13.01 Million | -50.88% |
| 2021-12-31 | $26.49 Million | +57.24% |
| 2020-12-31 | $16.84 Million | -2.25% |
| 2019-12-31 | $17.23 Million | -17.48% |
| 2018-12-31 | $20.88 Million | +230.60% |
| 2017-12-31 | $6.32 Million | +112.98% |
| 2016-12-31 | $2.97 Million | -37.31% |
| 2015-12-31 | $4.73 Million | -54.23% |
| 2014-12-31 | $10.34 Million | -34.74% |
| 2013-12-31 | $15.84 Million | +71.57% |
| 2012-12-31 | $9.23 Million | +212.87% |
| 2011-12-31 | $-8.18 Million | -330.65% |
| 2010-12-31 | $-1.90 Million | -171.95% |
| 2009-12-31 | $2.64 Million | +1589.23% |
| 2008-12-31 | $-177.25K | -121.62% |
| 2007-12-31 | $819.88K | -35.86% |
| 2006-12-31 | $1.28 Million | -27.85% |
| 2005-12-31 | $1.77 Million | -56.11% |
| 2004-12-31 | $4.04 Million | +17.34% |
| 2003-12-31 | $3.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oragenics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21439207600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.57K | % |
| Other Components | $216.56 Million | % |
| Total Equity | $-211.88K | 100.00% |
Oragenics Inc Competitors by Market Cap
The table below lists competitors of Oragenics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Winfarm
PA:ALWF
|
$2.74 Million |
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
$2.74 Million |
|
KC Property PLC
BK:KC
|
$2.74 Million |
|
Goyal Aluminiums Limited
NSE:GOYALALUM
|
$2.74 Million |
|
Tirta Mahakam Resources Tbk
JK:TIRT
|
$2.74 Million |
|
Roquefort Therapeutics plc
PINK:ROQAF
|
$2.73 Million |
|
Manufatura de Brinquedos Estrela SA
SA:ESTR3
|
$2.73 Million |
|
Bank Leumi Le-Israel B.M
TA:LUMI
|
$2.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oragenics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,168,154 to -211,885, a change of -3,380,039 (-106.7%).
- Net loss of 10,567,918 reduced equity.
- New share issuances of 6,671,830 increased equity.
- Other comprehensive income increased equity by 1,592,723.
- Other factors decreased equity by 1,076,674.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.57 Million | -4987.57% |
| Share Issuances | $6.67 Million | +3148.8% |
| Other Comprehensive Income | $1.59 Million | +751.69% |
| Other Changes | $-1.08 Million | -508.14% |
| Total Change | $- | -106.69% |
Book Value vs Market Value Analysis
This analysis compares Oragenics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $3104.60 | $0.79 | x |
| 2004-12-31 | $3455.86 | $0.79 | x |
| 2005-12-31 | $1410.49 | $0.79 | x |
| 2006-12-31 | $765.89 | $0.79 | x |
| 2007-12-31 | $392.10 | $0.79 | x |
| 2008-12-31 | $-60.66 | $0.79 | x |
| 2009-12-31 | $488.28 | $0.79 | x |
| 2010-12-31 | $-206.78 | $0.79 | x |
| 2011-12-31 | $-858.36 | $0.79 | x |
| 2012-12-31 | $312.31 | $0.79 | x |
| 2013-12-31 | $330.21 | $0.79 | x |
| 2014-12-31 | $171.54 | $0.79 | x |
| 2015-12-31 | $77.44 | $0.79 | x |
| 2016-12-31 | $39.89 | $0.79 | x |
| 2017-12-31 | $76.93 | $0.79 | x |
| 2018-12-31 | $96.09 | $0.79 | x |
| 2019-12-31 | $24.45 | $0.79 | x |
| 2020-12-31 | $17.88 | $0.79 | x |
| 2021-12-31 | $14.07 | $0.79 | x |
| 2022-12-31 | $6.48 | $0.79 | x |
| 2023-12-31 | $1.41 | $0.79 | x |
| 2024-12-31 | $-0.03 | $0.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oragenics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-137.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -48.63% | 0.00% | 0.00x | 1.06x | $-2.02 Million |
| 2004 | -76.25% | -1568.67% | 0.04x | 1.11x | $-3.48 Million |
| 2005 | -183.51% | 0.00% | 0.00x | 1.21x | $-3.43 Million |
| 2006 | -229.66% | -4436.23% | 0.04x | 1.26x | $-3.06 Million |
| 2007 | -281.99% | -1737.20% | 0.12x | 1.40x | $-2.39 Million |
| 2008 | 0.00% | -2578.58% | 0.15x | 0.00x | $-6.00 Million |
| 2009 | -209.08% | -860.62% | 0.20x | 1.21x | $-5.78 Million |
| 2010 | 0.00% | -596.26% | 0.76x | 0.00x | $-7.62 Million |
| 2011 | 0.00% | -531.79% | 1.14x | 0.00x | $-6.86 Million |
| 2012 | -141.79% | -982.73% | 0.13x | 1.14x | $-14.01 Million |
| 2013 | -101.45% | -1557.07% | 0.06x | 1.06x | $-17.65 Million |
| 2014 | -56.01% | -615.95% | 0.08x | 1.08x | $-6.82 Million |
| 2015 | -247.54% | -995.83% | 0.20x | 1.22x | $-12.18 Million |
| 2016 | -236.48% | 0.00% | 0.00x | 1.45x | $-7.31 Million |
| 2017 | -106.57% | 0.00% | 0.00x | 1.14x | $-7.36 Million |
| 2018 | -47.48% | 0.00% | 0.00x | 1.06x | $-12.00 Million |
| 2019 | -90.38% | 0.00% | 0.00x | 1.15x | $-17.30 Million |
| 2020 | -156.91% | 0.00% | 0.00x | 1.11x | $-28.12 Million |
| 2021 | -59.32% | -18062.03% | 0.00x | 1.07x | $-18.36 Million |
| 2022 | -109.83% | -10863.96% | 0.01x | 1.13x | $-15.59 Million |
| 2023 | -651.98% | -54858.14% | 0.01x | 1.57x | $-20.97 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.55 Million |
Industry Comparison
This section compares Oragenics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oragenics Inc (OGEN) | $9.83 Million | -48.63% | 0.29x | $2.74 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |